Matrix Capital Management Company LP Sells 1,173,684 Shares of Maze Therapeutics, Inc. $MAZE

Matrix Capital Management Company LP trimmed its position in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 71.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 480,000 shares of the company’s stock after selling 1,173,684 shares during the period. Maze Therapeutics comprises about 34.5% of Matrix Capital Management Company LP’s portfolio, making the stock its 2nd largest holding. Matrix Capital Management Company LP’s holdings in Maze Therapeutics were worth $19,886,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after purchasing an additional 362,060 shares in the last quarter. Woodline Partners LP boosted its position in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after buying an additional 94,529 shares during the period. Marshall Wace LLP boosted its position in shares of Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after buying an additional 758,104 shares during the period. ArrowMark Colorado Holdings LLC purchased a new position in shares of Maze Therapeutics during the third quarter worth $14,135,000. Finally, Geode Capital Management LLC boosted its position in shares of Maze Therapeutics by 11.3% during the fourth quarter. Geode Capital Management LLC now owns 527,281 shares of the company’s stock worth $21,850,000 after buying an additional 53,732 shares during the period.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $24.05 on Friday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.33 billion, a P/E ratio of -9.51 and a beta of 2.26. Maze Therapeutics, Inc. has a 52 week low of $9.83 and a 52 week high of $53.65. The company has a 50-day moving average price of $26.10 and a 200 day moving average price of $36.88.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. Research analysts predict that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total transaction of $73,600.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $381,689.60. The trade was a 16.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 89,502 shares of company stock valued at $2,733,139 in the last 90 days. Insiders own 5.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on MAZE. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Wedbush boosted their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. boosted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Finally, Guggenheim boosted their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.